文献速递外周动脉疾病

Viabahn覆膜支架治疗症状性外周动脉疾病股浅动脉病变的日本上市后监测研究12个月结果

Twelve-Month Outcomes From the Japanese Post-Market Surveillance Study of the Viabahn Endoprosthesis as Treatment for Symptomatic Peripheral Arterial Disease in the Superficial Femoral Arteries.
PubMed 文献 · J Endovasc Ther · 2021-12-15

日本前瞻性多中心上市后监测研究纳入321例症状性股浅动脉病变(长度≥10 cm)患者,12个月Kaplan-Meier估计的一期通畅率85.6%、一期辅助通畅率91.7%、二期通畅率94.8%,免于靶病变血运重建率92.3%,装置或操作相关严重不良事件累积10.6%,无支架断裂。

要点

  • 12个月一期通畅率85.6%、一期辅助通畅率91.7%、二期通畅率94.8%。
  • 12个月免于靶病变血运重建率92.3%,装置或操作相关严重不良事件累积10.6%。
  • 12个月X线评估未见支架断裂。

核心结论

  • 在股浅动脉长病变和复杂外周动脉疾病的日本真实世界人群中,Viabahn覆膜支架12个月通畅率优良且安全性可接受。

研究设计与样本

  • 日本前瞻性、多中心、上市后监测研究,2016年8月至2017年5月在64家日本中心纳入321例症状性股浅动脉病变长度≥10 cm、参考血管直径4.0至7.5 mm的患者。

主要发现

  • 12个月Kaplan-Meier估计的一期通畅率为85.6%,一期辅助通畅率为91.7%,二期通畅率为94.8%。
  • 12个月免于靶病变血运重建率为92.3%。
  • 30天内装置或操作相关严重不良事件发生率为3.1%,早期严重不良事件以入路并发症为主。
  • 12个月累积10.6%发生装置或操作相关严重不良事件,最常见为装置闭塞占4.0%。
  • 下肢截肢发生率为0.9%,3例均与既往溃疡或坏疽相关;12个月X线评估未见支架断裂。

关键数值与推荐

  • 入组标准为症状性股浅动脉病变长度≥10 cm且参考血管直径4.0至7.5 mm。
  • 排除胸、腹或盆腔动脉创伤性或医源性血管损伤患者。
  • 病变长度平均23.6 cm±6.6 cm,≥15 cm者占84.4%(271例)。
  • TASC C/D病变占86.6%(TASC C 39.1%,TASC D 47.5%),26.5%为严重肢体缺血。
  • 共植入562枚装置于324条肢体,68.8%的患者接受2枚支架。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the midterm safety and effectiveness of the Gore® Viabahn® Endoprosthesis as treatment for symptomatic peripheral arterial disease (PAD) in the superficial femoral arteries (SFA). MATERIALS AND METHODS: A prospective, multicenter, post-market surveillance study was conducted in Japan. Patients with symptomatic SFA lesions ≥ 10 cm and reference vessel diameters ranging from 4.0 to 7.5 mm were eligible for enrollment; patients with traumatic or iatrogenic vessel injury in the thoracic, abdominal, or pelvic arteries were excluded. Outcomes evaluated at 12 months were primary patency (PP), primary-assisted patency (PAP), secondary patency (SP), freedom from target lesion revascularization (fTLR), occurrence of device- or procedure-related serious adverse events (SAEs), and stent fractures. RESULTS: From August 2016 to May 2017, 321 patients were enrolled at 64 Japanese sites (mean age, 73.9±8.7 years; 77.3% male). Hypertension, diabetes, and end stage renal disease were present in 84.4%, 54.8%, and 23.1% of patients, respectively. Mean lesion length was 23.6 cm±6.6 cm, with lesions ≥ 15 cm in 271 patients (84.4%). TASC C/D lesions accounted for 86.6% (39.1% TASC C, 47.5% TASC D); 26.5% had critical limb ischemia. Baseline ABI was 0.60±0.16. A total of 562 devices were implanted in 324 limbs, with a majority of patients (68.8%) receiving 2 stents. Through 12 months, 92.1% of patients were evaluable. Kaplan-Meier-estimated PP, PAP, and SP at 12 months was 85.6%, 91.7%, and 94.8%, respectively. Twelve-month fTLR was 92.3%. Mean change in ABI at 12 months was 0.343±0.21; mean improvement in Rutherford class was 2.5. Device- or procedure-related SAEs occurred in 3.1% through 30 days, with a majority of early SAEs consisting of access complications. Through 12 months, a cumulative 10.6% had device- or procedure-related SAEs, with the most common being device occlusions in 4.0%. Lower limb amputation occurred in 0.9% and was related to pre-existing ulceration or gangrene in all 3 cases. No stent fractures were observed at 12-month x-ray evaluation. CONCLUSION: In a real-world Japanese patient population characterized by long SFA lesions and complex PAD, the Viabahn endoprosthesis was associated with excellent patency rates through 12 months and an acceptable safety profile.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Iida O, Ohki T, Soga Y, et al. Twelve-Month Outcomes From the Japanese Post-Market Surveillance Study of the Viabahn Endoprosthesis as Treatment for Symptomatic Peripheral Arterial Disease in the Superficial Femoral Arteries. J Endovasc Ther. 2021. PMID: 34905961. doi:10.1177/15266028211067739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。